Appealing her loss in a trade mark stoush with an Australian fashion designer, pop star Katy Perry has argued the woman “should have changed direction” with her ‘Katie Perry’ brand once the singer’s star began to rise.
A nose job patient who allegedly defamed his surgeon has been slugged with $50,000 in security for his appeal, on top of a $50,000 damages bill that a judge said the surgeon is unlikely to see.
A judge has handed a partial win to homewares brand Bed Bath N’ Table, finding rival House misled consumers by opening a sub-brand called House Bed & Bath but rejecting the retailer’s trade mark infringement claims.
Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.
The ACCC has raised concerns over Qantas’ alleged failure to respond to claims in a blockbuster case against the airline over the sale of tickets on cancelled flights.
German drug maker Boehringer has prevailed in its Federal Court fight against US rival Zoetis over the validity of three patents covering pig vaccines.
The owners of Mother energy drinks and Vittoria Food & Beverage have both lost their challenges to each other’s ‘Motherland’ and ‘Mothersky’ trade marks and are considering taking the long-running stoush to the High Court.
Mineral exploration company Boart Longyear has been granted leave to appeal a finding that it infringed a patent for a mining tool, but it can’t avoid a recall of its tools, with a judge saying its actions were “not uninformed or innocent”.
The maker of Finish dishwashing products has appealed a judgment that removed two of its trade marks for non-use and rejected its claim that a competitor’s logo was deceptively similar.
Swiss pharmaceutical company Biogen and Australian generic drug maker Pharmacor have dropped their claims against one another in a lawsuit over the patent for MS drug Tecfidera. In an October 14 order by Federal Court Justice Helen Rofe, Biogen’s infringement claims and Pharmacor’s cross-claims seeking to invalidate the lucrative patent were discontinued by consent without…